Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 2/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.55 |
| ▸ | CCND3 | P30281 | 1/20 | 0.55 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 6/20 | 0.53 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 3/20 | 0.52 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.51 |
| ▸ | FLT3 | P36888 | 2/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CDK7 | P50613 | 1/20 | 0.51 |
| ▸ | CCNH | P51946 | 1/20 | 0.51 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.51 |
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3250638 | 0.90 | JAK2 (0.58) | CDK4GSK3BEIF2AK2JAK2ACVR1 | |
| SCHEMBL3250434 | 0.89 | EIF2AK2 (0.56) | CDK4GSK3BEIF2AK2JAK2ACVR1 | |
| SCHEMBL3253119 | 0.89 | CDK2 (0.57) | CDK4GSK3BJAK2ACVR1CDK2 | |
| SCHEMBL3253139 | 0.89 | JAK2 (0.53) | CDK4GSK3BEIF2AK2JAK2ACVR1 | |
| SCHEMBL3247445 | 0.87 | EIF2AK2 (0.58) | CDK4GSK3BEIF2AK2JAK2ACVR1 | |
| SCHEMBL21526586 | 0.87 | ACVR1 (0.69) | CDK4GSK3BACVR1CDK2KDR | |
| SCHEMBL3253621 | 0.87 | JAK2 (0.56) | CDK4GSK3BCCND3EIF2AK2JAK2 | |
| SCHEMBL3252752 | 0.85 | CDK2 (0.57) | CDK4GSK3BEIF2AK2JAK2ACVR1 | |
| SCHEMBL3252685 | 0.84 | FLT3 (0.62) | CDK4GSK3BCCND3EIF2AK2JAK2 | |
| SCHEMBL3249231 | 0.84 | JAK2 (0.58) | CDK4GSK3BJAK2ACVR1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1521749-B8 | PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2010-12-22 | — | — | EP | claimed |
| EP-1521749-B1 | PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2010-05-19 | — | — | EP | claimed |
| US-7691855-B2 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives | NOVARTIS AG (CH) | 2010-04-06 | — | — | US | claimed |
| US-20060106027-A1 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives | FURET PASCAL | 2006-05-18 | — | — | US | claimed |
| EP-1521749-A1 | PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | Novartis AG (CH) | 2005-04-13 | — | — | EP | claimed |
| WO-2004005282-A1 | PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2004-01-15 | — | — | WO | claimed |
| EP-1521749-B1 | PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | NOVARTIS AG (CH) | 2010-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106027-A1 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives | MKI67, CCNI, PAH | CDK4 4/4885GSK3B 862/4885CCND3 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.